Improvement in Patient-reported Disease Severity, Cognitive Functioning, and Fatigue in Patients With Narcolepsy Type One Treated With Alixorexton, an Orexin Two Receptor Agonist, in the Vibrance-1 Phase Two Study (P6-14.002)

Neurology, vol. 106

Abstract

Describe the effect of once-daily alixorexton, an investigational, oral, highly selective orexin 2 receptor agonist, versus placebo on disease severity, cognition, and fatigue in patients with narcolepsy type 1 (NT1).

Authors 13

1. Yves A Dauvilliers

   Hôpital Gui de Chauliac

   Affiliation as printed

   Hopital Gui De Chaulliac

2. Ronald Grunstein

   Woolcock Institute of Medical Research · Macquarie University

   Affiliation as printed

   Woolcock Institute of Medical Research, Macquarie University

3. Emmanuel Mignot

   Stanford Medicine · Stanford University

   Affiliation as printed

   Stanford University School of Medicine

4. Gerrit Lammers Aachen

   Leiden University Medical Center

   Affiliation as printed

   Leiden University Medical Center

5. David Plante

   University of Wisconsin–Madison

   Affiliation as printed

   University of Wisconsin-Madison, School of Medicine and Public Health

6. Erik Buntinx
   Affiliation as printed

   ANIMA Research

7. Rafael del Río Villegas
   Affiliation as printed

   Neurophysiology and Sleep Disorders Unit, Vithas Madrid Hospitals

8. Hailu Chen

   Alkermes (United States)

   Affiliation as printed

   Alkermes, Inc

9. Craig Hopkinson

   Alkermes (United States)

   Affiliation as printed

   Alkermes, Inc

10. Bhaskar Rege

    Alkermes (United States)

    Affiliation as printed

    Alkermes, Inc

11. Julie Himes

    Alkermes (United States)

    Affiliation as printed

    Alkermes, Inc

12. Michael Doane

    Alkermes (United States)

    Affiliation as printed

    Alkermes, Inc

13. Giuseppe Plazzi

    Istituto delle Scienze Neurologiche di Bologna

    Affiliation as printed

    IRCCS Istituto delle Scienze Neurologiche di Bologna